GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Revenue

Tianda Pharmaceuticals (HKSE:00455) Revenue : HK$532.1 Mil (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Revenue?

Tianda Pharmaceuticals's revenue for the six months ended in Dec. 2023 was HK$228.6 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$532.1 Mil. Tianda Pharmaceuticals's Revenue per Share for the six months ended in Dec. 2023 was HK$0.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.25.

During the past 12 months, the average Revenue per Share Growth Rate of Tianda Pharmaceuticals was 4.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 5.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Tianda Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 62.40% per year. The lowest was -25.50% per year. And the median was 11.30% per year.


Tianda Pharmaceuticals Revenue Historical Data

The historical data trend for Tianda Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Revenue Chart

Tianda Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 527.00 491.48 474.33 509.96 532.09

Tianda Pharmaceuticals Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 236.52 273.44 249.86 303.48 228.61

Competitive Comparison of Tianda Pharmaceuticals's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianda Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Tianda Pharmaceuticals's Revenue falls into.



Tianda Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$532.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianda Pharmaceuticals  (HKSE:00455) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Tianda Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianda Pharmaceuticals (HKSE:00455) Business Description

Traded in Other Exchanges
N/A
Address
CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG
Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.
Executives
Tianda Group Limited 2101 Beneficial owner
Fang Wen Quan 2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines